Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Botox® (onabotulinumtoxinA) – Expanded indication
June 21, 2019 - Allergan announced the FDA approval of Botox (onabotulinumtoxinA), for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.
